Welcome to our dedicated page for Uniqure news (Ticker: QURE), a resource for investors and traders seeking the latest updates and insights on Uniqure stock.
uniQure N.V. (NASDAQ: QURE) is a gene therapy company that regularly issues news on its clinical programs, regulatory interactions, and financing activities. The company describes itself as delivering single‑treatment gene therapies with potentially curative results and has reported that the approvals of its gene therapy for hemophilia B mark a major milestone in genomic medicine. News about uniQure often highlights progress in its pipeline for Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe conditions.
A major focus of QURE news coverage is AMT‑130, uniQure’s investigational gene therapy for Huntington’s disease. Press releases and related SEC filings detail pivotal Phase I/II trial results, including statistically significant slowing of disease progression at 36 months in high‑dose cohorts compared to a propensity score‑matched external control, as well as trends in motor and cognitive endpoints and biomarker changes. Investors also see updates on the company’s regulatory dialogue with the U.S. Food and Drug Administration, including pre‑BLA and Type A meetings and feedback on the adequacy of Phase I/II data for a potential Biologics License Application.
Beyond AMT‑130, uniQure news includes early‑stage data and enrollment updates for AMT‑260 in refractory mesial temporal lobe epilepsy, AMT‑191 in Fabry disease, and AMT‑162 in SOD1 ALS. Corporate news items cover public offerings of ordinary shares and pre‑funded warrants, amendments to loan facilities, and quarterly financial results. This QURE news page aggregates such disclosures so readers can follow clinical milestones, regulatory developments, and capital markets events that shape uniQure’s gene therapy business over time.
uniQure N.V. (NASDAQ: QURE) announced its participation in three upcoming virtual investor and scientific conferences. The Truist Securities Life Sciences Summit is scheduled for May 4-5, 2021, featuring one-on-one meetings. The American Society of Gene and Cell Therapy (ASGCT) virtual event will take place from May 11-14, 2021, showcasing five data presentations, including two oral presentations on May 12 and 13. Finally, at the RBC Capital Markets Global Healthcare Conference on May 18-19, 2021, there will be additional virtual meetings and a fireside chat with CEO Matt Kapusta.
uniQure N.V. (NASDAQ: QURE) announced five data presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting from May 11-14. The presentations will focus on gene therapy advancements targeting hemophilia and Huntington’s disease, highlighting the AAV5 vector's efficacy amid pre-existing neutralizing antibodies. Notable sessions include two oral presentations on the Phase 3 HOPE-B trial and miQURE technology's proof-of-concept for liver targeting. These sessions aim to showcase uniQure's innovation in gene therapy for severe medical conditions.
uniQure N.V. (NASDAQ: QURE) has announced that the FDA has lifted the clinical hold on its hemophilia B gene therapy program, following a thorough review regarding a patient who developed hepatocellular carcinoma (HCC) during the HOPE-B trial. Investigations showed no evidence that the therapy contributed to the patient's condition. uniQure is set to release 52-week data from the HOPE-B trial soon. The company has conducted extensive monitoring of patients, with no further HCC cases reported across over 100 participants.
uniQure N.V. (NASDAQ: QURE) announced that three preclinical studies on its gene therapy candidate AMT-130 for Huntington's disease were published in notable journals. The studies demonstrate the safety and efficacy of AMT-130, which showed significant long-term reductions in mutant huntingtin protein levels in minipig models. At 12 months post-administration, reductions were 85% in the putamen and 80% in the caudate. The results support ongoing Phase I/II clinical trials for AMT-130, showcasing a promising biomarker for monitoring therapy.
uniQure N.V. announced the successful completion of patient enrollment in the first dose cohort of a Phase I/II clinical trial for AMT-130, aimed at treating early-stage Huntington's disease. The trial involves a total of 26 patients, with 10 in the first cohort and 16 planned for the second dose cohort, slated to begin in 3Q 2021. Additionally, uniQure intends to initiate an open-label clinical study in Europe later this year, potentially impacting an estimated 75,000 Europeans affected by Huntington's disease.
uniQure N.V. (NASDAQ: QURE) announced its participation in multiple upcoming virtual investor and scientific conferences. Key events include the Guggenheim Healthcare Talks on April 1, where management will engage in discussions on gene therapy challenges. Following this, the Wells Fargo Corporate Access Days will take place from April 6-8, and the Needham Virtual Healthcare Conference from April 12-15. Additional panels will cover topics related to Huntington's disease and patient advocacy. The company's pipeline focuses on therapies for various severe conditions including hemophilia and Huntington's disease.
uniQure N.V. (NASDAQ: QURE) announced that an independent investigation suggests etranacogene dezaparvovec is highly unlikely to have caused hepatocellular carcinoma (HCC) in a patient from the HOPE-B pivotal trial. The analysis of over 220,000 cells indicated rare AAV vector integration events, constituting just 0.027% of the sample, with no evidence of clonal expansion. The tumor exhibited genetic mutations indicative of HCC, independent of the vector. The company is preparing to discuss these findings with the FDA, emphasizing the safety of their gene therapy program.
uniQure N.V. (NASDAQ: QURE) reported significant developments in its gene therapy pipeline in a recent press release. Key highlights include the completion of patient procedures in the Phase I/II study for Huntington's disease and the HOPE-B trial for hemophilia B, which showed promising data. Financial results for 2020 showed revenues surged to $37.5 million from $7.3 million in 2019, largely due to licensing agreements. However, the company faced a net loss of $125 million. A strong cash position of $244.9 million positions them well for upcoming trials and regulatory filings.
uniQure N.V. (NASDAQ: QURE) has announced its participation in several upcoming virtual investor and scientific conferences. Key events include the Cowen 41st Annual Health Care Conference from March 1-4, featuring a panel on neurological therapies, and the H.C. Wainwright Global Life Science Conference on March 9-10 with a fireside chat by CEO Matt Kapusta. Additionally, the company will participate in the Gene Therapy for Blood Disorders workshop on March 9-11 and Gene Therapy Patient Engagement on March 23-25. The Stifel CNS Day will occur from March 31 to April 1.
uniQure (NASDAQ: QURE) announced positive progress in its Phase I/II clinical trial of AMT-130 for Huntington's disease. An independent Data Safety Monitoring Board confirmed no significant safety concerns after reviewing six-month safety data from the first two patients and 90-day data from two others. All remaining patients in the first cohort are cleared for enrollment, targeting full enrollment by mid-2021. The trial aims to assess safety, tolerability, and efficacy in 26 patients, with initial biomarker and imaging data expected by year-end 2021.